What Conditions Qualify for Medical Cannabis UK? (2026)

Chronic pain is by far the largest category of UK medical cannabis prescriptions — roughly 50–60% of all patients. Conditions that typically qualify include:

• Neuropathic nerve pain (post-herpetic neuralgia, diabetic neuropathy, sciatica).

• Fibromyalgia (widespread musculoskeletal pain).

• Osteoarthritis and rheumatoid arthritis.

• Chronic lower back pain with a structural or neurological diagnosis.

• Complex regional pain syndrome (CRPS).

• Trigeminal neuralgia.

• Severe endometriosis pain.

What UK clinics look for: a formal diagnosis from an NHS or private pain specialist, evidence of failed conventional treatment (typically gabapentinoids, opioids, NSAIDs, physiotherapy, or nerve root blocks), and a current Summary Care Record. Most clinics prescribe balanced THC:CBD flower or CBD-dominant oils as a starting regimen, escalating to higher THC formulations only if symptom relief is inadequate. Read our Chronic Pain Access Guide for the full prescribing pathway.

Psychiatric and mood disorders account for 25–30% of UK medical cannabis prescriptions. Conditions commonly accepted by specialist psychiatrists include:

• Generalized anxiety disorder (GAD).

• Post-traumatic stress disorder (PTSD / C-PTSD).

• Treatment-resistant depression.

• Social anxiety disorder and agoraphobia.

• Obsessive-compulsive disorder (OCD).

What UK clinics look for: documented failure of at least two first-line psychiatric treatments (typically an SSRI/SNRI plus a course of CBT or EMDR). Most clinics start patients on CBD-dominant formulations during the day and add low-dose THC formulations for sleep and acute anxiety. Pure high-THC products are usually avoided due to the risk of THC-induced paranoia in this population. For a deep dive, see our Cannabis & Mental Health Guide and our CBD vs THC for Anxiety comparison.

Adult ADHD is one of the fastest-growing prescription categories in UK clinics during 2025–2026. Many neurodivergent adults who did not respond well to stimulant medications (methylphenidate, lisdexamfetamine) are now exploring CBPMs as a complementary option.

Conditions that qualify under this category:

• Adult ADHD (with formal psychiatric diagnosis).

• Autism Spectrum Disorder — particularly for sensory overload, emotional regulation difficulties, and co-occurring sleep disturbance.

What UK clinics look for: a formal ADHD or ASD assessment from a psychiatrist or clinical psychologist, evidence of conventional treatment attempts (stimulant medication, atomoxetine, behavioural therapy), and clear documentation of which symptoms the patient hopes to address with cannabis. Most clinics prescribe balanced or CBD-leaning daytime formulations and a low-THC, myrcene-rich evening strain to support sleep. Read our Cannabis for ADHD guide for the full evidence base.

Neurological conditions are the original NHS-recognised category for medical cannabis. The 2018 rescheduling was specifically driven by cases of paediatric epilepsy and multiple sclerosis.

• Multiple Sclerosis (MS): cannabis-based medicines (Sativex / nabiximols) are licensed for MS-related spasticity. Private clinics also prescribe flower and oils for neuropathic pain, bladder dysfunction, and sleep disturbance.

• Epilepsy: CBD-dominant medicines (Epidyolex) are licensed on the NHS for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. Private clinics prescribe whole-plant CBPMs for treatment-resistant cases.

• Parkinson's disease: prescribed for tremor, dyskinesia, rigidity, and sleep disturbance.

• Dystonia & Tourette's syndrome: prescribed for muscle spasms and vocal tics.

What UK clinics look for: a consultant neurologist diagnosis, NHS records of failed first-line antiepileptic or anti-spasticity medications, and (for paediatric epilepsy) detailed seizure diaries.

Two smaller but well-established prescription categories:

• Crohn's disease, ulcerative colitis, and treatment-resistant irritable bowel syndrome (IBS): prescribed when biologics, immunosuppressants, or anti-spasmodics have failed.

• Chronic primary or secondary insomnia: prescribed when conventional sleep medications (melatonin, zopiclone, CBT-I) have proven inadequate or caused dependence. Most clinics target sleep through myrcene- and linalool-rich evening strains rather than high-THC daytime products. Read our Cannabis for Sleep guide for dosing and strain protocols.

Oncology is a smaller but clinically important category. Cannabis-based medicines are prescribed for:

• Chemotherapy-induced nausea and vomiting (CINV) when standard antiemetics (ondansetron, aprepitant) have failed. Nabilone (a synthetic THC) is licensed for this use.

• Cancer-related cachexia (loss of appetite and weight).

• Radiation-induced neuropathy.

• Palliative pain management in end-of-life care.

What UK clinics look for: oncology consultant referral, documented failure of standard antiemetics or analgesics, and clear goals of care.

To satisfy the Care Quality Commission (CQC) and General Medical Council (GMC) prescribing guidelines, all UK private clinics enforce the 'two-treatment rule.'

You must have a formal diagnosis from an NHS or private specialist and documented clinical evidence demonstrating that you have tried at least two conventional, licensed treatments or therapies that proved ineffective, provided inadequate symptom relief, or caused intolerable side effects requiring cessation.

What qualifies as a valid conventional treatment?

• Pharmaceutical medications (e.g. gabapentinoids, opioids, SSRIs, SNRIs, NSAIDs, biologics, antispasmodics).

• Psychotherapeutic interventions (e.g. Cognitive Behavioural Therapy / CBT, EMDR, talking therapies documented in NHS records).

• Physical and interventional therapies (e.g. physiotherapy, steroid joint injections, nerve root blocks, surgical procedures).

Documenting your history: You do not need a GP referral. You simply need to request your Summary Care Record (SCR) with additional information or your full medical history printout from your GP surgery (or download your health records via the NHS App).

Following your initial consultation with a specialist doctor (such as a consultant pain specialist or consultant psychiatrist), your case cannot be approved by that single doctor alone.

Under UK clinical governance, all new patient cases must be presented to a Multidisciplinary Team (MDT) panel — a committee of independent doctors, clinical pharmacists, and healthcare specialists.

The MDT reviews your diagnosis, medical history, past medication failures, and current drug regimen to ensure that prescribing cannabis is safe, ethical, and clinically justified before issuing your first prescription.

While private clinics treat a wide variety of conditions, strict absolute and relative contraindications exist to protect patient safety:

• History of Psychosis or Schizophrenia: Individuals with a personal medical history of schizophrenia, psychosis, or bipolar I disorder with manic psychosis are strictly excluded from receiving THC prescriptions due to the risk of triggering psychotic episodes.

• Pregnancy and Breastfeeding: CBPMs are strictly contraindicated during pregnancy and lactation due to potential risks to fetal and infant neurodevelopment.

• Severe Uncontrolled Cardiovascular Disease: Unstable angina, recent myocardial infarction (heart attack within 6 months), or severe uncontrolled arrhythmias may lead to refusal or restriction to non-THC formulations (pure CBD/CBG).

• Severe Hepatic or Renal Impairment: End-stage liver or kidney failure impairs the body's ability to metabolize and clear cannabinoids safely.

Different private clinics in the UK specialize in distinct clinical branches. For instance, some clinics focus heavily on pain management and rheumatology, while others possess dedicated psychiatric and neurodivergence panels specializing in ADHD, autism, and PTSD.

Before applying, verify that the clinic has a specialist on the GMC register dedicated to your specific condition. Most clinics offer a free, no-obligation pre-screening eligibility check online or over the phone prior to booking your paid consultation.